Pharmacyclics, Inc. (PCYC) news: Pharmacyclics: Facts Behind $10B Market Cap Seeking Alpha To date, first-line treatment has usually consisted of Roche's (OTCQX:RHHBY) monoclonal antibody Rituxan (rituximab) – which is directed against the CD20 antigen found on B lymphocytes – combined with a multi-agent chemotherapy regimen, most often ... |
